All In Biotech

Drug Trial Radar · NCT07326995

Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma

A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 24, 2025

Primary completion

Feb 2026

Study completion Mar 2026

Sponsor

Sponsor type
Industry
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Inhalation Aerosol in patients with bronchial asthma.

Conditions

  • Bronchial Asthma

Interventions

  • PA9159 Metered-Dose Inhaler, 60 μg per day for 28 daysDrug

    PA9159 of 60 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.

  • PA9159 Metered-Dose Inhaler, 120 μg per day for 28 daysDrug

    PA9159 of 120 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.

  • PA9159 Metered-Dose Inhaler, 240 μg per day for 28 daysDrug

    PA9159 of 240 μg is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.

  • Placebo Metered-Dose Inhaler without PA9159, Twice daily for 28 daysDrug

    Placebo is delivered orally through a metered-dose Inhaler , Twice daily for 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation the change in morning pre-dose forced expiratory volume in one second (FEV1) from baseline to week 4 of treatment.Time frame: From pre-dose until 28 days post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.